Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619
Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
0
3 Reasons Growth Investors Will Love Novo Nordisk (NVO)
https://www.zacks.com/stock/news/2220495/3-reasons-growth-investors-will-love-novo-nordisk-nvo?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-2220495
Feb 02, 2024 - Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
0
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
https://www.fool.com/investing/2024/02/08/heres-why-merck-eli-lilly-and-novo-nordisk-stocks/?source=iedfolrf0000001
Feb 08, 2024 - Investors are still excited about obesity treatments and weight-management drugs.
0
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190
Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
0
2 No-Brainer Biotech Stocks to Buy Right Now
https://www.fool.com/investing/2024/02/21/2-no-brainer-biotech-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 21, 2024 - These stocks are used to beating the market.
0
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
https://www.fool.com/investing/2024/03/05/a-new-competitor-to-wegovy-could-be-on-the-way-sho/?source=iedfolrf0000001
Mar 05, 2024 - Here's why I'm not worried.
0
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study
https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238077
Mar 08, 2024 - Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
0
Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?
https://www.zacks.com/stock/news/2239193/novo-nordisk-nvo-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2239193
Mar 12, 2024 - Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
All You Need to Know About Novo Nordisk (NVO) Rating Upgrade to Buy
https://www.zacks.com/stock/news/2239424/all-you-need-to-know-about-novo-nordisk-nvo-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2239424
Mar 12, 2024 - Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
The Zacks Analyst Blog Highlights Novo Nordisk, Tesla, Airbnb, ONEOK and CDW
https://www.zacks.com/stock/news/2240060/the-zacks-analyst-blog-highlights-novo-nordisk-tesla-airbnb-oneok-and-cdw?cid=CS-ZC-FT-press_releases-2240060
Mar 13, 2024 - Novo Nordisk, Tesla, Airbnb, ONEOK and CDW are part of the Zacks top Analyst Blog.
0